Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Page 325

Big deal: Element Science factors in $145m series C

Uday Kumar, whose previous spinout iRhythm is trading with a market cap of $2.6bn, has collected $145.6m in a GV-backed round for his latest venture.

Mar 9, 2020

Pager calls in $33m

Horizon Blue Cross Blue Shield of New Jersey took part in an equity and debt round for medical communication app developer led by Health Catalyst Capital.

Mar 9, 2020

Flavin flaunts return to university venturing

Portal Innovations will target biomedical spinouts from across the Midwest under the direction of ex-UChicago innovation veteran John Flavin.

Mar 9, 2020

Woodford sounds out appetite for $655m fund

Neil Woodford could return to the stage with a bid for some of his old assets should ongoing talks with unnamed UK-based institutional investors and wealth managers succeed.

Mar 9, 2020

Corporate venturing deal net: 2-6 March 2020

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Mar 6, 2020

Culture Biosciences gets $15m funding reaction

MIT Media Lab-affiliated E14 Fund has invested in the biomanufacturing software provider as part of a series A round led by Cultivian Sandbox Ventures.

Mar 6, 2020

Recipharm returns for latest Cinclus round

Cinclus Pharma has lured back corporate venturing unit Recipharm Venture Fund for a $26.4m round that will fund a phase 2 study for its GERD therapy candidate.

Mar 6, 2020

GV helps pump series C funding into Element

The wearable defibrillator developer, founded by Stanford adjunct professor Uday Kumar, has raised more than $145m that will support the launch of its lead product.

Mar 6, 2020

Oric originates IPO filing

The Taiho Ventures, Memorial Sloan and Hartford HealthCare Endowment-backed cancer drug developer has filed to raise up to $86.3m.

Mar 5, 2020

Novartis helps plant $100m in Pliant

Pliant Therapeutics has attracted $100m in a series C round led by Novartis, four years after it was founded to commercialise UC San Francisco research into fibrosis treatment.

Mar 4, 2020
© 2026 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here